Menu

Recent Interviews

Jim Payne, CEO, dynaCERT Inc.

Jim Payne
CEO | dynaCERT Inc.
101-501 Alliance Avenue, M6N 2J1 Toronto, Ontario (CAN)

jpayne@dynacert.com

+1 416 766 9691

dynaCERT CEO Jim Payne on attractive hydrogen opportunities


Sebastian-Justus Schmidt, CEO and Founder, Enapter AG

Sebastian-Justus Schmidt
CEO and Founder | Enapter AG
Ziegelhäuser Landstraße 1, 69120 Heidelberg (D)

info@enapterag.de

Enapter AG CEO and founder Sebastian-Justus Schmidt on the future of hydrogen


John Jeffrey, CEO, Saturn Oil & Gas Inc.

John Jeffrey
CEO | Saturn Oil & Gas Inc.
Suite 1000 - 207 9 Ave SW, T2P 1K3 Calgary, AB (CAN)

jjeffrey@saturnoil.com

+1-587-392-7900

Saturn Oil & Gas CEO John Jeffrey on the future of the company and ESG


23. December 2020 | 08:50 CET

Q & M Dental, Moderna, AstraZeneca: Serving people!

  • Health
Photo credits: Q & M Dental Group

Rarely has the stock market been so focused on people as it has been during the pandemic. People are thinking about which companies offer the best service package for all the problems associated with infections, vaccinations and even the psychological effects of isolation and loneliness. Humans are "social animals" with multiple social needs. Curtailing these needs works temporarily, but at some point, the arguments have to be genuinely purposeful so that certain restrictions continue to be accepted. At the peak of the contagion curve, we would like to see possible remedies that quickly turn the overall situation into a positive end - this is possible for the medium-term future. Still, in the short term, we have to stick together.

time to read: 4 minutes by André Will-Laudien


 

Author

André Will-Laudien

Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

About the author


Q & M Dental Group - Asian health care player grows properly

Q & M Dental Group is a Singapore-based dental service provider with its main product Invisalign, which is also successfully used in Europe to correct misaligned teeth. In addition to Europe and the USA, the market is also growing strongly in Asia at around 12% per year. Together with its subsidiaries, the group is a leading private dental service provider in Singapore with a growth of over 20% per annum.

Expansion plans are already in place for Malaysia, the People's Republic of China and other ASEAN countries. Currently, they operate 114 dental clinics, 5 medical clinics and 3 dental supplies and equipment distribution companies. Supported by more than 230 experienced dentists and nearly 400 employees, the group has more than 300,000 patients in Singapore. In addition to general and specialized dental and medical care, the group has also invested in postgraduate training with the establishment of the Q & M School.

Since April this year, it has also been offering tools for Covid-19 testing centers together with its partner Acumen Diagnostics. As a result, revenue shortfalls during lockdown periods can be bridged in the best possible way. Revenue will reach about 128 million Singapore dollars (SGD) in 2020, with pre-tax profit adding up to SGD 20 million. The share price has already moved decently this year between SGD 0.30 and SGD 0.73. At the current price of SGD 0.46, the market capitalization is SGD 362 million. With these growth figures, Q & M is therefore not too expensive. Admittedly, it needs accessible practices to deliver services to patients unimpeded again, so one should expect the share price to pick up nicely by summer at the latest.

Moderna - vaccine in the approval phase

Moderna Inc. is a US biotech Company specializing in the research and development of drugs based on mRNA. mRNA drugs are designed to enable the body's cells to produce proteins with therapeutic or preventive effects that can help treat various diseases. Applications for mRNA products include therapeutics and vaccines for cancer immunotherapies, rare diseases, cardiovascular diseases, autoimmune diseases and inflammation. The Company's consistent progress in basic and applied mRNA research enables parallel new developments, both independently and with strategic partners.

In the US, the first people were administered the US Company Moderna's Corona vaccine on Monday. CNN television showed doses of the vaccine being administered at a hospital in Houston, Texas. On the short messaging service Twitter, hospitals in Ohio and Connecticut, among others, posted photos of doctors and nurses receiving the vaccine. The United States is the first country in the world to use the substance away from testing. Before the end of the year, 20 million units could be available in the US, according to the Company; in Europe, a meeting on possible approval is set for Jan. 6, 2021.

According to analyst estimates, Moderna Inc. is expected to climb from 2019 sales of USD 60 million to more than USD 500 million this year, and USD 7 billion in 2021 because of the pandemic. Profits could explode to about USD 2 billion next year, giving the Company a P/E ratio of just 22 on a capitalization of USD 44 billion. Currently, it is not yet making a profit. The share price has already risen by 600% in the last 12 months.

AstraZeneca - pharmaceutical giant may soon deliver

AstraZeneca plc is a Swedish-British Pharmaceutical Company engaged in the development, production and marketing of prescription drugs. AstraZeneca's research focuses primarily on respiratory, cardiovascular and metabolic, cancer, inflammatory, infection and neurological disorders. The Company offers medicines for asthma, heart attacks, breast and prostate cancer, diabetes, and the treatment of depression, schizophrenia, and bipolar disorder. The Company was formed in 1999 through the Swedish group Astra's merger, founded back in 1913, with the British Company Zeneca.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has not yet decided whether to approve the Covid-19 vaccine. The review is ongoing to ensure that any approved vaccine meets the expected high safety standards, quality and efficacy. Previously, the Daily Telegraph reported that the vaccine, which AstraZeneca is developing in collaboration with the prestigious University of Oxford, should receive approval before the end of December. Unfortunately, we are not there yet. Meanwhile, a mutation of the Covid-19 virus has already emerged on the island, and the EU is responding with travel measures.

The European Union has already ordered several 100 million doses from AstraZeneca. In total, billions of doses have already been ordered worldwide. The promising active ingredient AZD1222 is based on an attenuated version of a cold virus from chimpanzees. It contains the genetic material of a surface protein with which the pathogen Sars-CoV-2 attaches to human cells. The drug has a twofold effect: it promotes the formation of both specific antibodies and T cells - both of which are important for immune defense.

AstraZeneca plc is among the 10 largest pharmaceutical companies globally, with a market capitalization of a whopping GBP 100 billion. The turnover is about GBP 22 billion, the bottom-line profit is GBP 3.5 per share, so the P/E ratio is about 20. In contrast to its industry peers, AstraZeneca lost about 5% over the year - but there is a 2.8% dividend.


Author

André Will-Laudien

Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

27. October 2020 | 10:17 CET | by André Will-Laudien

Pfizer, GlaxoSmithKline, EXMceuticals - Research in competition

  • Health

By the end of 2020, the drug market is expected to more than double to USD 1.3 trillion, with the E7 countries - Brazil, China, India, Indonesia, Mexico, Russia and Turkey - accounting for about one-fifth of global drug sales. Also, the incidence of chronic diseases in developing countries will increasingly resemble that in industrialized countries. The evidence is abundant that the pharmaceutical industry business model is both economically unsustainable and operationally lethargic to produce the types of innovative treatments demanded by global markets. The industry must fundamentally change the way it operates to take full advantage of future growth opportunities. PwC's management consultants expect the industry to shift its focus from treatment to prevention. The traditional blockbuster sales model will disappear, and sophisticated direct sales channels will diminish the role of wholesalers. Let's take a closer look!

Read

29. September 2020 | 10:51 CET | by Mario Hose

BioNTech, Bayer, Valeo Pharma: Share price jump ahead of quarterly results

  • Health

Investors' expectations of developments can drive the share price. When it comes to solving a problem or creating needs, the interest of the capital market is particularly high. Things get exciting for investors when the business model offers the possibilities of scalability. Attractive investment opportunities can be created in the fields of health and medicine, which offer extraordinary return opportunities.

Read

29. July 2020 | 07:29 CET | by Mario Hose

BioNTech, Eastman Kodak, EXMceuticals - investors have the chance to profit

  • Health

The importance of health has not been as clear for a long time as it was in 2020. Detached from the discussion about the specifics of COVID-19 on mortality compared to other viruses, the need for protection is great and helplessness without a medical response is harmful to the common good. For this reason, experts around the globe are working to find active ingredients and reduce dependence on China for care. Investors have the opportunity to profit from this development.

Read